David Fenard

Years Active: 2015-2022
Publications (10 Years): 2

Sangamo Therapeutics

Université de Nice Sophia Antipolis UFR Sciences (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Sangamo Therapeutics Oct 01 2018

France

Director Cell Engineering

TxCell SA Jan 02 2017 - Sep 30 2018

France

Director Gene Transfer :: Cell Engineering

Généthon Jan 09 2008 - Dec 21 2016

France

Team leader :: R&D - Technological Innovation Lentivirus

Education History

Université de Nice Sophia Antipolis UFR Sciences

France

PHD

Publications

Emma Proics, Marion David, Majid Mojibian, Madeline Speck, Nadia Lounnas-Mourey, Adeline Govehovitch, Wissam Baghdadi, Justine Desnouveaux, Hervé Bastian, Laura Freschi, Geoffrey Privat, Cédric Pouzet, Mauro Grossi, Pierre Heimendinger, Tobias Abel, David Fenard, Megan K Levings, François Meyer, Céline Dumont
Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation. Gene therapy (2022)
Saliha Majdoul, Jeremie Cosette, Ababacar K Seye, Eric Bernard, Sophie Frin, Nathalie Holic, Nathalie Chazal, Laurence Briant, Lucile Espert, Anne Galy, David Fenard
Peptides derived from evolutionarily conserved domains in Beclin-1 and Beclin-2 enhance the entry of lentiviral vectors into human cells. The Journal of biological chemistry 292 (45) (2017)
Saliha Majdoul, Ababacar K Seye, Antoine Kichler, Nathalie Holic, Anne Galy, Burkhard Bechinger, David Fenard
Molecular Determinants of Vectofusin-1 and Its Derivatives for the Enhancement of Lentivirally Mediated Gene Transfer into Hematopoietic Stem/Progenitor Cells. The Journal of biological chemistry 291 (5) (2015)

David Fenard.css-eqlu8i{font-size:small;padding-left:4px;}